Redaktion

Viele Menschen mit Psoriasis nutzen digitale Medien, um sich auszutauschen und mehr über ihre Krankheit zu erfahren[1][2]. Sie fühlen sich online weniger allein mit ihren Problemen, weil sie sehen, dass andere ähnliches erleben. Das kann das Wohlbefinden stärken. Viele finden im Internet neue Therapieideen oder Selbsthilfegruppen. Besonders praktisch für Leute mit starker Bewegungseinschränkung sind Online-Angebote, etwa digitale Treffen[1]. Es gibt aber auch Probleme. Manche Inhalte sind schlecht gemacht, manche wollen einfach nur Produkte verkaufen[1][2]. Oft tauschen Patienten sich online aus, sprechen aber nicht mit ihren Ärzten über ihr digitales Wissen, weil sie negative Reaktionen befürchten[2][3]. Die meisten wünschen sich, dass Ärzte bessere Online-Angebote empfehlen und mit Plattformen zusammenarbeiten. So könnten alle von digitalen Möglichkeiten profitieren und Fehlinformationen würden weniger[2][3]. Originaltitel: Beyond the screen: exploring digital health experiences of individuals affected by psoriasis – a qualitative interview study - BMC Public Health Link zur Quelle

Eine neue Studie zeigt: **TNF-alpha-Hemmer** können das Risiko für Psoriasis-Arthritis (PsA) bei schwerer Schuppenflechte deutlich senken. Forschende verglichen über fast zehn Jahre zwei Gruppen: Die eine nahm TNF-alpha-Hemmer, die andere bekam Lichttherapie. In der TNF-alpha-Gruppe bekamen weniger als halb so viele Menschen PsA wie in der Lichttherapie-Gruppe[2][1]. Vor allem Menschen mit Schmerzen in den Gelenken, Nagelbeteiligung oder einem hohen Schuppenflechte-Score haben ein größeres Risiko für PsA. Die Forschenden vermuten, dass TNF-alpha-Hemmer nicht nur die Haut, sondern auch das Immunsystem so beeinflussen, dass neue Gelenkentzündungen verhindert werden[2][3]. Diese Ergebnisse sind wichtig für alle mit schwerer Psoriasis, denn sie zeigen: Wer die Entzündung früh und gezielt stoppt, kann womöglich auch seine Gelenke schützen[2]. Originaltitel: TNF-alpha inhibitors reduce the incidence of PsA in patients with psoriasis: a propensity score-matched cohort study Link zur Quelle

Viele Menschen mit Psoriasis suchen online nach Infos zu ihrer Krankheit[1]. Das hilft oft, sich besser zu fühlen und neue Therapien zu entdecken[1]. Leider gibt es auch viele schlechte Webseiten und Werbung[1]. Die meisten sprechen mit ihren Ärzt*innen nicht über das, was sie im Internet finden[1]. Falls sie es doch machen, sind die Reaktionen der Ärzt*innen meist kritisch[1]. Die Befragten wünschen sich mehr gute und sichere Infos im Netz und bessere Zusammenarbeit zwischen Ärzt*innen und Online-Plattformen[1]. Ärzte sollten ihre Patient*innen zu verlässlichen Seiten begleiten und gemeinsam mit ihnen digitale Angebote nutzen[1]. Originaltitel: Beyond the screen: exploring digital health experiences of individuals affected by psoriasis - a qualitative interview study. Link zur Quelle

Viele Menschen nutzen mittlerweile **ätherische Öle** als natürliche Alternative in Hautpflegeprodukten. Studien zeigen: **Teebaumöl hilft gut gegen Akne**, Lavendel- und Rosmarinöle wirken oft **entzündungshemmend** und können das **Hautbild verbessern**. Auch Kamillen- und Basilikumextrakte bringen Vorteile für die Haut. Es gibt Cremes, Gele und Seren, die unterschiedlich stark **Feuchtigkeit spenden** und die Haut elastischer machen. Trotzdem sagen Forschende: Für ein klares Urteil über Wirkung und Sicherheit fehlen noch langfristige, große Studien[1][2]. Originaltitel: Evaluating efficacy, safety, and innovation in skin care applications of essential oils: a systematic review. Link zur Quelle

Eine neue Studie aus Deutschland zeigt: Ein digitales Programm kann Betroffenen mit Rheuma, Psoriasis arthritis oder Lupus helfen, sich psychisch besser zu fühlen[1][2][4]. Die Teilnehmenden bekamen entweder das digitale Training oder die Standardbehandlung. Nach drei Monaten ging es denen mit Online-Unterstützung deutlich besser. Sie hatten weniger Ängste und Depressionen. Auch ihre Lebensqualität stieg spürbar[1][4]. Solche digitalen Angebote sind sicher, einfach nutzbar und könnten in Zukunft mehr Menschen helfen, die auf psychologische Hilfe angewiesen sind[2][3]. Das Programm ist besonders praktisch, weil es unabhängig vom Aufenthaltsort funktioniert[1][2]. Originaltitel: Digital Psychological Intervention for Inflammatory Rheumatic Diseases: A Pilot Randomized Clinical Trial. Link zur Quelle

Eine Studie zeigt, dass **Inulin** bei Menschen mit Rheuma die Entzündungswerte verbessern kann und das allgemeine Befinden steigt[1]. Inulin ist ein Ballaststoff, der als Futter für gute Darmbakterien dient[5]. Diese Bakterien sind wichtig für unser Immunsystem. Besonders bei Rheuma lohnt sich ein gesunder Darm, weil dann weniger schädliche Stoffe ins Blut gelangen, die Entzündungen anfeuern können[3]. Die Studie legt nahe, dass Inulin Schmerzen und andere Beschwerden verringern kann, sodass der Alltag leichter fällt[1]. Inulin gibt's zum Beispiel in Chicorée, Topinambur und als Pulver. Wer es ausprobieren will, sollte langsam starten, um Blähungen zu vermeiden[5]. Originaltitel: Inulin supplementation improves some inflammatory indices, clinical outcomes, and quality of life in rheumatoid arthritis patients Link zur Quelle

Das Gen **SLC16A10** spielt bei Psoriasis eine wichtige Rolle[1]. Es reguliert den Stoffwechsel der **Arachidonsäure** in Hautzellen, den sogenannten Keratinozyten[1]. Das beeinflusst die Entzündung und kann dazu führen, dass sich Psoriasis verschlimmert oder wiederkehrt. SLC16A10 wirkt dabei auch auf das Gleichgewicht der Schilddrüsenhormone, was ebenfalls einen Einfluss auf die Entstehung der Krankheit hat[1]. Wenn das Gen heruntergeregelt wird, werden die Entzündung und die Beschwerden bei Psoriasis schwächer[1]. Außerdem könnte SLC16A10 auch nach der Entzündung die Haut heller machen, da es die Bildung von Pigmenten hemmt[1]. Forschende sehen SLC16A10 als neuen Ansatz für die Diagnose und Therapie von Psoriasis, vor allem bei der Form der **guttaten Psoriasis**[1]. Originaltitel: Role of SLC16A10 in Psoriasis Through the Regulation of Arachidonic Acid Metabolism in Keratinocytes. Link zur Quelle

Bei einer seltenen Genveränderung im NFKBIA-Gen, genauer die p.Gln228*-Mutation, funktioniert das Eiweiß IκBα nicht richtig. Dadurch kann ein wichtiger Botenstoff, NFκB1, nicht mehr normal in den Zellkern wandern. Betroffene aus einer Familie, in der mehrere Mitglieder unter Arthritis und Psoriasis leiden, zeigten durch diese Mutation Anzeichen von Autoinflammation. Anders als bekannte Fehler an der Spitze (N-Terminus) des IκBα, die zu schwerer Immunschwäche führen, verursachen Veränderungen am Ende (C-Terminus) eher Entzündungen wie bei Psoriasis und Gelenkbeschwerden[1]. Originaltitel: A germline IκBα mutation outside the signal reception domain blocks nuclear translocation of NFκB1 and associates with autoinflammation-like features. Link zur Quelle

Menschen mit Multipler Sklerose (MS) haben oft auch andere Autoimmunerkrankungen wie Schuppenflechte oder Hashimoto[2]. Forschende haben jetzt untersucht, ob diese zusätzlichen Krankheiten den Verlauf der schubförmigen MS verschlechtern. Bei rund 17 Prozent der 861 MS-Patienten in der Studie gab es mindestens eine weitere Autoimmunerkrankung, am häufigsten Hashimoto, danach Psoriasis. Das Ergebnis: Ob jemand noch an Psoriasis oder Co. erkrankt ist, hat keinen Einfluss auf die Schubrate, die Behandlung oder das Fortschreiten der Behinderung bei schubförmiger MS[2][1]. Originaltitel: The impact of autoimmune comorbidities on multiple sclerosis progression: insights from a longitudinal single-center study. Link zur Quelle

Menschen mit Prurigo nodularis (PN) haben ein höheres Risiko, an bestimmten Autoimmunerkrankungen zu erkranken. Eine große Studie mit fast 18.000 PN-Betroffenen zeigte, dass sie über doppelt so häufig Lupus oder Sjögren-Syndrom bekommen wie Menschen ohne PN. Ihr Risiko für eine Schuppenflechte ist sogar dreimal so hoch. Besonders Frauen mit PN sind öfter von Lupus oder Sjögren betroffen, Männer bekommen häufiger Schuppenflechte. Für andere Erkrankungen wie rheumatoide Arthritis oder chronische Darmentzündungen gibt es bei PN aber kein erhöhtes Risiko. Die Ergebnisse sprechen dafür, dass Ärztinnen und Ärzte bei PN häufiger auf Autoimmunkrankheiten achten sollen[1]. Originaltitel: New-onset Autoimmune Diseases in Patients with Prurigo Nodularis: A Global-federated Retrospective Cohort Study. Link zur Quelle

Patienten mit Psoriasis haben öfter Bluthochdruck als Menschen ohne Psoriasis. Das gilt besonders für alle mit Psoriasis arthritis. Fast jeder dritte Mensch mit Psoriasis hat auch Bluthochdruck, bei Psoriasis arthritis ist es sogar mehr als jeder Dritte[1][2]. Das bedeutet: Wer Psoriasis arthritis hat, sollte gezielt auf Bluthochdruck untersucht werden[1][2]. Das Risiko steigt, je schwerer die Schuppenflechte ist. Fachleute empfehlen daher, den Blutdruck regelmäßig zu messen, um Folgeerkrankungen früh zu erkennen. Warum Bluthochdruck gerade bei Psoriasis häufiger auftritt, erforschen Wissenschaftler noch. Originaltitel: Epidemiology of hypertension in psoriasis: An analysis of trends from | PTT Link zur Quelle

Immer mehr Studien zeigen: Die Gesundheit unseres Darms spielt eine große Rolle bei Autoimmunerkrankungen wie Psoriasis oder Psoriasis-Arthritis[1][2]. Es gibt Hunderte verschiedene Bakterienarten im Darm, die unser Immunsystem beeinflussen. Wenn das Gleichgewicht dieser Bakterien gestört ist, nennt man das Dysbiose. Dysbiose kann Entzündungen im Körper fördern und Autoimmunreaktionen verstärken[2][3]. Forscher sehen zum Beispiel, dass bei Betroffenen oft bestimmte schädliche Bakterien vermehrt vorkommen[3]. Ein gesunder Darm könnte also helfen, das Immunsystem zu beruhigen. Es gibt Hinweise, dass Probiotika oder eine ausgewogene Ernährung hier unterstützen können, aber mehr Forschung ist nötig[4]. Originaltitel: Exploring the Relationship Between Gut Health and Autoimmune Diseases: A Systematic Review and Meta-Analysis Link zur Quelle

Menschen mit Psoriasis haben ein erhöhtes Risiko für Herz-Kreislauf-Erkrankungen und psychische Probleme[1][2]. Forschende haben jetzt untersucht, wie Medikamente aus der Gruppe der GLP-1-Rezeptor-Agonisten (GLP-1RA), die eigentlich bei Diabetes und Übergewicht eingesetzt werden, dieses Risiko beeinflussen[1][2][3]. Die Ergebnisse zeigen: Wer Psoriasis hat und mit GLP-1RA behandelt wird, hat ein geringeres Risiko für Herzinfarkt, Schlaganfall und psychische Erkrankungen[1][2][3]. Auch die Sterblichkeit war niedriger als bei Menschen mit Psoriasis, die diese Medikamente nicht bekamen[1]. Der Schutz war besonders stark im Vergleich zu Menschen ohne Psoriasis[1]. GLP-1RA gelten als sicher und könnten für Menschen mit Psoriasis und zusätzlichen Risikofaktoren wie Übergewicht oder Diabetes besonders hilfreich sein[1][3]. Ergebnisse aus mehreren Studien deuten darauf hin, dass sowohl die Haut als auch das Herz vom Medikament profitieren[3]. Originaltitel: GLP-1RA and reduced mortality, cardiovascular and psychiatric risks in psoriasis: a large-scale cohort study | British Journal of Dermatology | Oxford Academic Link zur Quelle

Viele Menschen mit Schuppenflechte haben Rückenschmerzen, die nicht zu den typischen Merkmalen von axialer Spondyloarthritis nach ASAS-Kriterien passen. Die ATTRACT-Studie zeigt: Auch wenn der Rückenschmerz erst nach dem 45. Lebensjahr beginnt oder nur kurz anhält, kann eine axiale Psoriasis-Arthritis (axPsA) vorliegen. Von 50 untersuchten Betroffenen in dieser Gruppe hatten 12 % eine aktive axPsA. Diese Patienten waren meist älter und hatten seltener entzündliche Rückenschmerzen, aber ähnlich aktive Erkrankungen wie Vergleichspatienten. Die Studie belegt: Auch bei untypischem Rückenschmerz lohnt der Blick auf axPsA[1]. Originaltitel: Axial psoriatic arthritis in patients not fulfilling the back pain entry features of the ASAS Classification Criteria for Axial Spondyloarthritis: findings from the ATTRACT Study. Link zur Quelle

No abstract supplied.Weiterlesen

The underlying mechanisms of atherosclerosis and strategies for identifying high cardiovascular risk in psoriasis are incompletely understood. Platelet activity is increased in psoriasis and induces vascular dysfunction. We investigated the platelet phenotype and platelet transcriptome as one potential mechanism to explain cardiovascular risk in psoriasis. Psoriasis and controls underwent platelet aggregation and activation studies and platelet RNA sequencing to generate a psoriasis platelet transcriptomic score. The relationship between the platelet transcriptomic score and cardiovascular risk was assessed by arterial stiffness, coronary calcium, and longitudinally in an independent cohort of high cardiovascular-risk individuals undergoing lower extremity arterial revascularization. Psoriasis subjects (n=73; median age, 51 years; body surface area of psoriasis, 3%) compared with controls (n=56; median age, 41 years) trended older (P=0.08) and had greater body mass index (P=0.01) and higher hs-CRP (high-sensitivity C-reactive protein) values (P=0.01). Platelet aggregation in response to collagen (P=0.0049) and ADP (P=0.033), and leukocyte-, neutrophil-, and lymphocyte-platelet aggregates (P<0.05 for each comparison) were all higher in psoriasis versus controls. Platelet RNA sequencing comparing 51 patients with psoriasis with 39 controls identified 329 upregulated and 345 downregulated genes (P<0.05). Pathway analysis identified dysregulated platelet activation, apoptosis, VEGF, interferon, senescence, IL (interleukin)-1, and clotting cascade signaling between psoriasis and controls. Using a phenotypic rank-based scoring methodology, a psoriasis platelet transcriptomic score comprised of 142 genes differentiated psoriasis from controls. This score correlated with arterial stiffness (r=0.26; P=0.031) and coronary calcium (r=0.58; P=0.0069). In a separate cohort of high cardiovascular-risk patients undergoing lower extremity arterial revascularization, the psoriasis platelet transcriptomic score is associated with incident myocardial infarction (adjHR, 3.7 [95% CI, 1.4-10.1]; P=0.015). Platelet aggregation and activation are increased in patients with controlled psoriatic disease, with the platelet transcriptome associated with proinflammatory, proatherothrombotic pathways, and cardiovascular risk. Our results warrant further investigation of platelet involvement promoting heightened cardiovascular disease in psoriasis.Weiterlesen

BackgroundPsoriasis is associated with a significant comorbidity burden, especially cardiovascular and metabolic complications. Glucagon-like peptide-1 receptor agonists (GLP-1RA), such as semaglutide, used to treat obesity and diabetes, could potentially reduce comorbidity in patients with psoriasis.ObjectiveTo investigate all-cause mortality, cardiovascular, inflammatory, psychiatric outcomes, and adverse events in psoriasis patients treated with GLP-1RA.MethodsThis retrospective population-based cohort study utilized real-world data from the US TriNetX database. Patients with psoriasis who were treated for diabetes or obesity with GLP-1RA during the full follow-up period of 2 years were compared with those treated with other systemic anti-diabetic or obesity drugs. After 1:1 propensity-score matching for relevant risk factors, 3,048 participants were included in each cohort. The primary outcomes included the risk of cardiometabolic, psychiatric, and autoimmune sequelae of psoriasis, as well as all-cause mortality and potential adverse drug events. The analysis was repeated using cohorts without psoriasis and results were further validated through two sensitivity analyses involving (i) later follow-up periods, or (ii) exclusion of patients with pustular psoriasis.ResultsIn the matched cohorts of 3,048 patients with psoriasis treated with GLP-1RA (60.37% females, mean age 56.94 years, standard deviation [SD] 12.02 years) versus other antidiabetic and obesity drugs (61.91% females, mean age 56.42 years, SD 14.16 years), GLP-1RA treatment was associated with significantly decreased all-cause mortality (hazard ratio [HR] 0.219, 95% confidence interval [CI] 0.123-0.391, p<0.0001) and reduced risk for major adverse cardiac events (MACE, HR 0.561, 95% CI 0.442-0.714, p<0.0001). Additionally, lower risks for alcohol (HR 0.346, CI 0.174-0.685, p=0.009) and substance abuse (HR 0.510, CI 0.350-0.743, p=0.002) were observed. Typical adverse drug events were not more frequent in the GLP-1RA cohort. The risk reductions were more pronounced in the cohorts with psoriasis compared to persons with obesity or diabetes without psoriasis. Findings were consistent across all sensitivity analyses.ConclusionsGLP-1RA treatment was safe and associated with reduced risks of cardiovascular and psychiatric comorbidities, as well as lower mortality in patients with psoriasis, with risk reductions markedly higher than in cohorts without psoriasis. Physicians should consider this drug class for patients with psoriasis and comorbid obesity or diabetes.Weiterlesen

ObjectiveSecondary failure to biologic DMARDs (bDMARDs) is challenging and contributes to the complexity of managing psoriatic arthritis (PsA). We aimed to define the frequency and incidence of this phenomenon in PsA and identify the risk factors for its occurrence.MethodsWe retrieved data on PsA patients from our single-centre, specialized-care, prospective observational cohort who initiated and remained on bDMARDs for ≥1 year after clinic enrollment between 2000 and 2023. We defined response to therapy at the one-year visit (baseline) as achievement of ≥40% reduction in the swollen joint count (SJC) and either ≥50% reduction in PASI or PASI ≤2. We defined secondary failure as the inability to maintain response criteria or as the clinician's judgment of loss of effectiveness. To examine factors associated with secondary failure, we fitted Cox regression models.ResultsOf 482 patients included in the study, 264 (54.8%) were responders at one year. Of these, 94 (35.6%) developed secondary failure at a median of 1.6 [IQR: 0.7, 3.8] years from response. In the multivariable model, higher SJC (HR 1.39, 95% CI 1.05-1.84) and PASI (HR 1.14, 95% CI 1.01-1.29) at baseline were associated with secondary failure. TNFi vs. other bDMARD use (HR 0.39, 95% CI 0.18-0.88), initiation as first-line bDMARD (HR 0.48, 95% CI 0.25-0.91), and treatment initiation during more recent calendar years (HR 0.34, 95% CI 0.12-0.98) were associated with less secondary failure.ConclusionSecondary failure to bDMARDs is common in PsA and may be influenced by both disease- and therapy-related factors.Weiterlesen

BackgroundPsoriatic disease (PsD) is a chronic, multisystem, inflammatory disorder encompassing psoriasis, psoriatic arthritis (PsA), and their associated comorbidities.ObjectiveThe aim of this subanalysis of the global "Psoriasis and Beyond" study was to evaluate patients' experiences of living with PsD in the USA.MethodsThe study included a cross-sectional, quantitative, 25-min online survey of adults with self-reported, healthcare professional-diagnosed, moderate-to-severe psoriasis, with or without PsA. USA-based patients were recruited through online panels by the Institut de Publique Sondage D'Opinion Secteur and The National Psoriasis Foundation.ResultsThis analysis included 793 US patients with psoriasis; 43% also had PsA. Overall, 75% of patients knew that their disease was systemic, and 65% had heard the term "psoriatic disease." Of patients without diagnosed PsA, 50% screened positive for PsA using the Psoriasis Epidemiology Screening Tool. Psoriasis negatively affected emotional well-being and quality of life (QoL) in the majority of patients (87% and 91%, respectively). Overall, 29% of patients reported that they could not work or study in the week prior to the survey; of these, 98% responded that psoriasis had a very or extremely large impact on their QoL. Mean diagnostic delays of 3.7 and 3.3 years for psoriasis and PsA, respectively, were reported.ConclusionsThis analysis of USA-based patients with PsD highlights the profound impact of PsD on emotional well-being and QoL and suggests potential underdiagnosis of PsA. There is a need to ensure early PsD diagnosis and to provide holistic treatment, including mental health support.Weiterlesen

Psoriasis and hypertension (HTN) are known to be closely related. However, at present, no study has systematically examined the epidemiology of this disease pattern on a global scale. We examined six databases from their inception until November 1, 2023 and used the Agency for Healthcare Research and Quality and the Newcastle-Ottawa Scale to assess the quality of observational studies. Data analysis was conducted in R. Meta-regression, sensitivity, and subgroup analyses were used to evaluate interstudy heterogeneity. Egger's test and funnel plots were used to evaluate publication bias. We reviewed 200 studies involving 15,010,888 patients. The overall prevalence of HTN among the patients with psoriasis was 32.22%. Overall, South America had the highest prevalence of hypertension among adult patients with psoriasis (52.36%), the three countries with the highest prevalence were Serbia, Singapore and Brazil. The prevalence of mild and severe psoriasis comorbid with HTN was 31.71% [95% CI: 24.40-40.05%] and 33.19% [95% CI: 27.17-39.81%], respectively. The prevalence of HTN in psoriasis vulgaris was 29.71% [95% CI: 25.10-35.15%], while that in psoriatic arthritis was 34.54% [95% CI: 31.27-38.14%]. Patients with psoriatic arthritis are more predisposed to requiring hypertension risk screening than patients with psoriasis vulgaris. More population-based prospective observational studies are required to elucidate the mechanisms underlying the coexistence of hypertension in patients with psoriasis.Weiterlesen

Psoriasis is an incurable and recurrent skin disease, and the need to develop new strategies for the treatment of psoriasis persists. Smilax glabra Roxb. (SGR) is listed as a key traditional Chinese medicine for the treatment of psoriasis through medicinal bath therapy in "Guideline for the diagnosis and treatment of psoriasis in China"; the active ingredients responsible for its anti-psoriatic effects and their mechanisms of action still require in-depth research. In this study, we first found that the topical application of SGR extract showed an anti-psoriasis effect in mice by using IMQ-induced primary and recurrent psoriasis mouse model. Network pharmacology, molecular docking, supercoiled DNA relaxation assay, luciferase reporter gene assay, and animal pharmacodynamics revealed that astilbin, quercetin, and resveratrol were key anti-psoriatic compounds in SGR extract for treating psoriasis by inhibiting TOP2A and activating AhR. These findings suggested that the synergistic effect of TOP2A inhibition and AhR activation was the key mechanism of SGR for the treatment of psoriasis. The combination of AhR activation and TOP2A inhibition synergistically alleviated psoriasis-like lesions and ameliorated the relapse of psoriasis-like lesions in mice. AhR activation and TOP2A inhibition synergistically regulated the cytokine-cytokine receptor interaction pathway and keratinization progress to prevent the relapse of psoriasis. This study investigates the "multi-component, multi-target" mechanism of SGR in treating psoriasis from the perspective of the interaction between targets, providing a new strategy for psoriasis topical treatment: the combination of TOP2A inhibitors and AhR activators.Weiterlesen

BackgroundThe nature of the relationship between psoriasis and alcohol consumption has been the topic of discussion for many years. Some studies have found that a higher intake of alcohol may be associated with a more severe manifestation of the disease. At the same time, patients with psoriasis often demonstrate elevated levels of alcohol consumption. It has not yet been fully established whether alcohol abuse serves as a trigger for psoriasis or if patients with psoriasis are simultaneously more prone to alcohol abuse.ObjectiveThe objective of this study was to employ Google Trends as a tool for crowdsourcing data on a national level to explore the relationship between psoriasis and the consumption of alcohol in Sweden.MethodsThis study examines crowdsourced web search data related to psoriasis and other skin disease-related search terms (such as utslag [rash]) as well as search interest in different types of alcohol. The analysis covers a 5-year period from 2018 to 2023 in Sweden, focusing on search behavior and correlations across this period.ResultsThe search behavior regarding psoriasis and alcohol-related search terms showed seasonal variations throughout the year. The relative search volume for psoriasis peaked in February, while alcohol-related searches, particularly Systembolaget and vodka, peaked in December and June. Our statistical analysis revealed relationships between the search interest regarding psoriasis and terms related to alcohol consumption, with disparities between different types of alcohol. The term "psoriasis" was negatively correlated with "Systembolaget" (r=-0.210), "vitt vin" (r=-0.224), and "vodka" (r=-0.220) (all P<.001), while the term "utslag" showed positive correlations with these same alcohol-related terms (r=0.278-0.347; P<.001).ConclusionsCrowdsourced data can offer valuable insights into population-level behavior. The observed negative correlations between psoriasis and alcohol-related searches suggest complex interactions, possibly reflecting reduced disease awareness or care during periods of higher alcohol consumption. The direction and strength of the correlations with psoriasis were not consistent across the different types of alcohol investigated in this study, which poses the question whether the relationship might be influenced by the type of beverage consumed. Further research is warranted to explore underlying mechanisms and validate these findings in clinical populations.Weiterlesen

BackgroundPsoriasis is a chronic immune-mediated skin disease that significantly impacts patients' quality of life due to its physical, psychological, and systemic burden. Phosphodiesterase-4 (PDE-4) plays a pivotal role in the inflammatory cascade of the disease through the modulation of intracellular cyclic adenosine monophosphate (cAMP) levels. This systematic review evaluates current evidence on the clinical efficacy and safety of novel PDE-4 inhibitors in the treatment of psoriasis.MethodsA systematic search was conducted in PubMed/Medline, Ovid Embase, and Web of Science databases through January 18th, 2025, to identify clinical studies evaluating PDE-4 inhibitors in patients with psoriasis. Methodological quality and risk of bias were assessed using the National Institutes of Health (NIH) quality assessment tool and the Murad et al.quality assessment tool.ResultsOut of 1,942 related studies, twelve studies with 642 patients met our inclusion criteria. Among oral PDE-4 inhibitors, oral roflumilast demonstrated consistent improvements in the Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI), as well as patient-reported outcomes, in cases with moderate to severe plaque psoriasis. Gastrointestinal symptoms were the most common adverse events. Similarly, orismilast and ME3183 also demonstrated significant PASI reductions and favorable tolerability, while topical agents like crisaborole and PF-07038124 showed a rapid localized response in patients suffering from mild to moderate psoriasis, with minimal adverse effects in sensitive areas, including the face and intertriginous regions.ConclusionPDE-4 inhibitors, both oral and topical, demonstrate promising efficacy and acceptable safety profiles in the treatment of psoriasis. To confirm their long-term benefits and improve clinical use, larger-scale studies with longer follow-up and a wider range of patients are required.Weiterlesen

BackgroundPsoriasis is an immune-mediated chronic inflammatory condition characterized by significant neutrophil infiltration in the skin. Given that the spleen is the largest peripheral immune organ in the body, it is important to investigate whether it has any impact on skin inflammation in psoriasis.MethodsTo investigate this mechanism, a psoriatic mouse model was established by IMQ application. Flow cytometry and immunohistochemistry analyses were performed to determine the percentage of various immune cells in the spleen. The role of neutrophils was specifically assessed using the anti-Gr-1 antibody. Splenic granulopoiesis was evaluated using EdU labeling. To understand the spleen's role in skin inflammation, splenectomy was performed on the experimental mice. IL-6 levels were measured by ELISA, and P-STAT3 in neutrophils was detected via immunofluorescence. Further examination of IL-6's effects on neutrophil formation involved treating mice with IL-6 antibody. The severity of psoriasis was evaluated through histological staining and PASI scoring.ResultsOur study revealed that the spleens of psoriatic mice were enlarged compared to those of vehicle mice. Among immune cell populations, neutrophils showed the most significant changes, with marked increases in both spleen and skin of psoriatic mice and patients, contributing to disease progression. Post-splenectomy, neutrophil infiltration in the skin was reduced by approximately 60% in psoriatic mice. This indicates that the neutrophils in the skin were primarily derived from the spleen. Additionally, the spleen showed a notable capacity for granulopoiesis with elevated neutrophils. Moreover, we found elevated IL-6 levels in the skin, blood, and spleen in the model, which was decreased after splenectomy. Treatment with an IL-6 antibody reduced neutrophil formation in both the spleen and skin, which alleviated skin inflammation in psoriatic mice. Additionally, P-STAT3 signaling was decreased following IL-6 antibody treatment. The neutrophil infiltration in spleen and skin was decreased after injection with the inhibitor of P-STAT3, which also alleviated the inflammation of psoriatic model. Thus, IL-6 served as the dominant regulator of spleen granulopoiesis, a process potentially mediated by P-STAT3 signaling.ConclusionsThe spleen plays a crucial role in the immune microenvironment of psoriasis as a major site of granulopoiesis, influencing neutrophil infiltration in the skin of psoriatic mice. Additionally, IL-6 is a key regulator of neutrophil formation in the spleen of psoriatic mice, likely through P-STAT3-dependent mechanisms.Weiterlesen

Psoriasis is an autoimmune skin disease associated with increased incidence and severity of chronic kidney disease and hypertension. The mechanisms linking psoriasis skin inflammation with these comorbidities remain unclear. We used flow cytometry, radiotelemetric blood pressure measurements, and histological and ELISA-based assessments of renal damage in mice with experimental psoriasis induced by keratinocyte-specific overexpression of Tie2 (KC-Tie2) and their littermate controls. Compared with littermate controls, KC-Tie2 mice with chronic skin inflammation developed albuminuria, histological evidence of glomerulosclerosis, and elevated blood pressure. KC-Tie2 mice had a selective and marked increase in circulating and renal neutrophils, along with increased neutrophil extracellular trap formation in the kidneys by flow cytometry. KC-Tie2 mice also exhibited increased bone marrow granulopoiesis along with increases in cutaneous and systemic G-CSF (granulocyte colony-stimulating factor), the primary mediator of granulopoiesis. Finally, neutralization of G-CSF decreased renal neutrophils and kidney damage in KC-Tie2 mice. Our findings demonstrate G-CSF-dependent increases in renal neutrophil accumulation and renal damage in a mouse model of psoriasis. Results suggest a novel link between chronic psoriasiform skin inflammation and renal damage via G-CSF-mediated granulopoiesis, providing new insight into interorgan communication in psoriasis and a potential new therapeutic target for the treatment of psoriasis-related renal dysfunction.Weiterlesen